MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024.
Highlights:
“We are pleased to see firm utilization, led by Pediatrics and in Critical Care, driving first-quarter revenue,” said Nestor Jaramillo, President and CEO of Nuwellis. “Increased awareness of the clinical and economic benefits of the Aquadex system continues to result in healthy utilization gains demonstrating increased therapy adoption as we navigate capital sales cycles. We look forward to continued positive momentum and growth in 2024 as we provide increased access optionality and a new source of revenue with our new 12 cm catheter, advance our pilot phase with DaVita, and begin to commercialize Quelimmune™ SCD under our exclusive license and distribution agreement with SeaStar Medical (Nasdaq “ICU”).”
First Quarter 2024 Financial Results
Revenue for the first quarter of 2024 was $1.9 million, a 2% increase compared to the prior-year period. The year-over-year increase is attributable to an 11% increase in consumable sales.
Gross margin was 64.1% for the first quarter of 2024, compared to 58.4% in the prior-year period. The increase was primarily due to higher manufacturing volumes of consumables.
Selling, general and administrative expenses for the first quarter of 2024 decreased to $4.6 million, compared to $5.5 million in the prior-year period. The decrease in SG&A expenses was primarily due to reduced headcount and compensation-related expense and lower corporate administrative expenses.
First quarter research and development expenses were $1.3 million, compared to $1.4 million in the prior-year period.
Total operating expenses for the first quarter of 2024 were $5.9 million, a 14% decrease compared to $6.9 million in the prior-year period. The $1 million decrease was due to cost saving measures implemented early in the second half of 2023 and carried forward to the current period as we continue to drive operating efficiencies.
Operating loss for the first quarter of 2024 decreased to $4.7 million compared to an operating loss of $5.8 million in the prior-year period.
Net loss attributable to common shareholders for the first quarter of 2024 was $3.8 million, or a loss of $0.60 per basic and diluted common share, compared to a net loss attributable to common shareholders of $6.5 million, or a loss of $5.76 per basic and diluted common share in the prior-year period.
At March 31, 2024, the Company had no debt, cash and cash equivalents of approximately $1.4 million, and approximately 6.8 million common shares outstanding. On April 30, Nuwellis closed an underwritten public offering with gross proceeds of $2.7 million before deducting underwriting discounts and commissions related to the offering.
Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10188299. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
| PART I—FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |||||||||||||||
| March 31, 2024 | December 31, 2023 | ||||||||||||||
| (Unaudited) | |||||||||||||||
| ASSETS | |||||||||||||||
| Current assets | |||||||||||||||
| Cash and cash equivalents | $ | 1,400 | $ | 3,800 | |||||||||||
| Accounts receivable | 1,226 | 1,951 | |||||||||||||
| Inventories, net | 2,131 | 1,997 | |||||||||||||
| Other current assets | 440 | 461 | |||||||||||||
| Total current assets | 5,197 | 8.209 | |||||||||||||
| Property, plant and equipment, net | 681 | 728 | |||||||||||||
| Operating lease right-of-use asset | 664 | 713 | |||||||||||||
| Other assets | 120 | 120 | |||||||||||||
| TOTAL ASSETS | $ | 6,662 | $ | 9,770 | |||||||||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | |||||||||||||||
| Current liabilities | |||||||||||||||
| Accounts payable and accrued liabilities | $ | 3,332 | $ | 2,380 | |||||||||||
| Accrued compensation | 725 | 525 | |||||||||||||
| Current portion of operating lease liability | 221 | 216 | |||||||||||||
| Other current liabilities | 45 | 51 | |||||||||||||
| Total current liabilities | 4,323 | 3,172 | |||||||||||||
| Common stock warrant liability | 964 | 2,843 | |||||||||||||
| Operating lease liability | 488 | 544 | |||||||||||||
| Total liabilities | 5,775 | 6,559 | |||||||||||||
| Commitments and contingencies | |||||||||||||||
| Mezzanine Equity Series J Convertible Preferred Stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 82 and 11,950, respectively | 2 | 221 | |||||||||||||
| Stockholders’ equity Series A junior participating preferred stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | |||||||||||||
| Series F convertible preferred stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 127 shares | — | — | |||||||||||||
| Preferred stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 39,352,000 shares, none outstanding | — | — | |||||||||||||
| Common stock as of March 31, 2024 and December 31, 2023, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,801,443 and 5,682,461, respectively | 1 | 1 | |||||||||||||
| Additional paid-in capital | 292,880 | 290,646 | |||||||||||||
| Accumulated other comprehensive income: | |||||||||||||||
| Foreign currency translation adjustment | (40 | ) | (31 | ) | |||||||||||
| Accumulated deficit | (291,956 | ) | (287,626 | ) | |||||||||||
| Total stockholders’ equity | 885 | 2,990 | |||||||||||||
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $ | 6,662 | $ | 9,770 | |||||||||||
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | ||||||
| Three months ended March 31 | ||||||
| 2024 | 2023 | |||||
| Net sales | $ | 1,857 | $ | 1,826 | ||
| Cost of goods sold | 666 | 759 | ||||
| Gross profit | 1,191 | 1,067 | ||||
| Operating expenses: | ||||||
| Selling, general and administrative | 4,606 | 5,490 | ||||
| Research and development | 1,334 | 1,428 | ||||
| Total operating expenses | 5,940 | 6,918 | ||||
| Loss from operations | (4,749 | ) | (5,851 | ) | ||
| Other income (expense), net | (101 | ) | 123 | |||
| Change in fair value of warrant liability | 522 | (755 | ) | |||
| Loss before income taxes | (4,328 | ) | (6,483 | ) | ||
| Income tax expense | (2 | ) | (2 | ) | ||
| Net loss | (4,330 | ) | (6,485 | ) | ||
| Deemed dividend attributable to Series J Convertible Preferred Stock | 541 | — | ||||
| Net loss attributable to common shareholders | $ | (3,789 | ) | $ | (6,485 | ) |
| Basic and diluted loss per share | $ | (0.60 | ) | $ | (5.76 | ) |
| Weighted average shares outstanding – basic and diluted | 6,286,298 | 1,125,993 | ||||
| Other comprehensive loss: | ||||||
| Net loss | $ | (4,330 | ) | $ | (6,485 | ) |
| Unrealized gain on marketable securities | — | 6 | ||||
| Foreign currency translation adjustments | (9 | ) | (7 | ) | ||
| Total comprehensive loss | $ | (4,339 | ) | $ | (6,486 | ) |
| NUWELLIS, INC. AND SUBSIDIARY Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | ||||||||
| Three months ended March 31 | ||||||||
| 2024 | 2023 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (4,330 | ) | $ | (6,485 | ) | ||
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
| Depreciation and amortization | 76 | 86 | ||||||
| Stock-based compensation expense | 158 | 181 | ||||||
| Change in fair value of warrant liability | (522 | ) | 755 | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 725 | 105 | ||||||
| Inventory, net | (134 | ) | (81 | ) | ||||
| Other current assets | 21 | (81 | ||||||
| Other assets and liabilities | (6 | ) | (16 | ) | ||||
| Accounts payable and accrued expenses | 1,150 | (570 | ) | |||||
| Net cash used in operating activities | (2,862 | ) | (6,106 | ) | ||||
| Investing Activities: | ||||||||
| Additions to intangible assets | — | (85 | ) | |||||
| Purchases of property and equipment | (29 | ) | (13 | ) | ||||
| Net cash used in investing activities | (29 | ) | (98 | ) | ||||
| Financing Activities: | ||||||||
| Issuance costs related to 2022 common stock offering | — | (11 | ) | |||||
| Proceeds from the exercise of Series J Convertible Preferred Warrants | 500 | — | ||||||
| Net cash provided by (used in) financing activities | 500 | (11 | ) | |||||
| Effect of exchange rate changes on cash | (9 | ) | (7 | ) | ||||
| Net decrease in cash and cash equivalents | (2,400 | ) | (6,222 | ) | ||||
| Cash and cash equivalents - beginning of period | 3,800 | 17,737 | ||||||
| Cash and cash equivalents - end of period | $ | 1,400 | $ | 11,515 | ||||
| Supplemental cash flow information | ||||||||
| Issuance of Series J Preferred Stock for exercise of Warrants | $ | 1,857 | $ | — | ||||
| Issuance of Common Stock for conversion of Series J Preferred Stock | $ | 1,535 | $ | — | ||||
| Deemed dividend on Series J Preferred Stock | $ | 541 | $ | — | ||||
| Last Trade: | US$1.17 |
| Daily Change: | -0.04 -3.31 |
| Daily Volume: | 522,879 |
| Market Cap: | US$2.190M |
November 04, 2024 November 01, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
